News | September 24, 2009

Prostate Cancer Foundation Convenes the World’s Leading Cancer Researchers

Jonathan W. Simons, M.D., president and CEO of the PCF.

September 25, 2009 - Nearly of 300 of the world’s leading researchers focused on the problem of prostate cancer will begin a three-day meeting today to discuss the latest scientific data and breakthroughs in prostate cancer. The meeting, held in Incline Village at Lake Tahoe in Nevada, is the 16th Scientific Retreat sponsored by the Prostate Cancer Foundation (PCF).

This year, it is projected that prostate cancer will take the lives of 27,000 U.S. men while 192,000 new cases are diagnosed. While the death rate from prostate cancer has been reduced by nearly 40 percent from what was once projected, the number of new cases diagnosed each year continues to rise. By 2015, the annual number of new cases may grow to 300,000.

“This meeting takes on additional urgency as it has been more than two years since there has been a government-sponsored meeting of this kind,” said Dr. Howard Soule, executive vice president and chief scientist for the PCF. “This annual meeting is a catalyst for scientific exchange and has helped accelerate scientific discovery for prostate cancer during the past decade. Some of the most promising developments on the field have come out of this meeting and the work of PCF-funded scientists.”

Scientists who are funded by the PCF are required to share updates on their project and share data at the PCF’s annual scientific retreat. This year’s meeting will include presentations on the progress of several new medications, therapies and biomarkers that hold promise for patients. A total of 81 scientific presentations on new research on treatment and prevention of early and advanced prostate cancers from 98 cancer research centers will be featured. The new data to be discussed originate from research programs in nine countries: Australia, Belgium, Canada, Israel, Italy, the Netherlands, Norway, the United Kingdom, and the United States. Since its founding, the PCF has raised more than $370 million to fund prostate cancer research that otherwise would have been left unfunded.

"An outcome of this international conference for accelerating better treatment for prostate cancer will be a new ‘game-changing research projects’ blueprint,” says Jonathan W. Simons, M.D., president and CEO of the PCF. “The PCF will be rapidly presenting the blueprint to our funding partners in prostate cancer research at the NIH, National Cancer Institute, Department of Defense, and leaders in the biotech and pharmaceutical industry. We want to remember this meeting as changing the course of prostate cancer research history for patients.”

The Prostate Cancer Foundation is the world’s largest philanthropic source of support for prostate cancer research focused on discovering better treatments and a cure for prostate cancer.

For more information:

Related Content

First GammaTile Therapy Case Completed in Arizona
News | Radiation Therapy | August 19, 2019
HonorHealth Scottsdale Osborn Medical Center is the first hospital in Arizona to begin offering GammaTile Therapy, a...
Drug Accelerates Blood System's Recovery After Radiation, Chemotherapy

Following radiation, the bone marrow shows nearly complete loss of blood cells in mice (left). Mice treated with the PTP-sigma inhibitor displayed rapid recovery of blood cells (purple, right). Credit: UCLA Broad Stem Cell Research Center/Nature Communications

News | Radiation Therapy | August 16, 2019
A drug developed by UCLA physician-scientists and chemists speeds up the regeneration of mouse and human blood stem...
Mevion and C-RAD Release Integration for Improved Proton Therapy Treatment Quality

Catalyst PT image courtesy of C-RAD

News | Patient Positioning Radiation Therapy | August 15, 2019
Mevion Medical Systems and C-RAD announced the integration between the C-RAD Catalyst PT and the Mevion S250i proton...
First Patient Enrolled in World's Largest Brain Cancer Clinical Trial
News | Radiation Therapy | August 15, 2019
Henry Ford Cancer Institute is first-in-the-world to enroll a glioblastoma patient in the GBM AGILE Trial (Adaptive...
Efficacy of Isoray's Cesium Blu Showcased in Recent Studies
News | Brachytherapy Systems | August 14, 2019
August 14, 2019 — Isoray announced a trio of studies recently reported at scientific meetings and published in medica
MD Anderson to Expand Proton Therapy Center

The MD Anderson Proton Therapy Center expansion is expected to be completed in 2023. Rendering courtesy of Stantec.

News | Proton Therapy | August 08, 2019
The University of Texas MD Anderson Cancer Center unveiled plans to expand its Proton Therapy Center during a...
IBA Signs Contract to Install Proton Therapy Center in Kansas
News | Proton Therapy | August 06, 2019
IBA (Ion Beam Applications S.A.) recently signed a contract and received the first payment for a Proteus One solution...
Varian Showcases Cancer Care Systems and Software at AAPM 2019
News | Radiation Therapy | August 02, 2019
Varian showcased systems and software from its cancer care portfolio, including the Identify Guidance System, at the...
Laura Dawson, M.D., FASTRO, Chosen as ASTRO President-elect
News | Radiation Oncology | July 31, 2019
The members of the American Society for Radiation Oncology (ASTRO) elected four new officers to ASTRO’s Board of...